宇宙神经动力学 开始了人类第一次试验 IV Psilocin 用于狂欢饮食紊乱。 Entropy Neurodynamics began the first human trial of IV psilocin for binge eating disorder.

Entropy Neurodynamics已启动全球首个使用静脉注射裸盖素（TRP-8803）治疗暴食症的临床试验，并于2025年12月1日为首位患者施药。 Entropy Neurodynamics has begun the world’s first clinical trial using intravenous psilocin, in the form of TRP-8803, to treat binge eating disorder, dosing its first patient on December 1, 2025. 这项与斯温伯恩大学合作进行的试验旨在评估静脉注射药物的安全性,耐受性和潜在疗效,这使得与口服psilocybin相比,更精确地控制了迷幻体验. The trial, conducted with Swinburne University, aims to evaluate the safety, tolerability, and potential efficacy of the IV formulation, which allows for more precise control over the psychedelic experience compared to oral psilocybin. 这标志着在探索新颖的BED治疗方法方面迈出了重要一步,BED是一种只有有限有效药物的情况。 This marks a significant step in exploring novel treatments for BED, a condition with limited effective medications.